mercredi 5 avril 2017

Onco Actu du 5 avril 2017

2. Etiologie

Antibiotics overuse could increase bowel cancer risk, study finds [The Guardian]

2.5 Etiologie - Gènes

Random Mutations Play Major Role in Cancer [NIH Director's Blog]

3.3 Prévention - Vaccins

Vaccine credited with HPV virus reduction in Scotland [BBC News]

4. Dépistage, diagnostic et pronostic

Method may help myeloma patients avoid painful biopsies [MIT News]

4.7 Dép., diag. & prono. - Col de l'utérus

Improving consistency in the diagnosis of cervical pre-cancers: Roche CINtec Histology test receives FDA clearance [Roche]

5.10 Traitements - Essais

Journal editor calls for ‘culture change’ around clinical trial data [STAT]

5.12.2 Immunothérapies - CAR-T

Making CAR T-Cell Therapy Safer [The Scientist]

5.12.5 Immunothérapies - Pharma

Rivals multiplying, Pfizer appeals to doctor preferences with Ibrance's latest label win [FiercePharma]

5.2 Pharma

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer [BMS]

Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse [The Street]

5.2.1 Pharma - Partenariats

Incyte Is Smart to Date Around [Bloomberg]

5.3 Traitements - FDA, EMA, NICE...

ASCO Releases Position Statement on Access to Investigational Drugs [ASCO]

Conflicts surround Trump's FDA pick [CNN]

5.4 Traitements - Economie

NICE turns down Shire's pancreatic cancer treatment [Pharmafile]

5.5 ASCO

Nanobiotix Expands its Clinical Development in Head and Neck Cancer and Immuno-Oncology - New Clinical Data to Be Presented at ASCO [Nanobiotix]

5.9.3 AACR - mélanome

Adding the IDO-pathway Inhibitor Indoximod to Pembrolizumab Improved the Melanoma Response Rate [AACR]

New Immunotherapy Combination Shows Promise for Patients With Advanced Melanoma [AACR]

AACR Annual Meeting 2017: Increasing the Number of Melanoma Patients Who Benefit From Immunotherapy [Cancer Research Catalyst]

Small biotech — big ambitions. Viralytics’ oncolytics therapy makes the showcase round at #AACR17 with positive combo snapshot [EndPoints]

5.9.4 AACR - poumon

Patients with Lung Cancers Responsive to Immunotherapy Drug Beat Standard Odds of Survival [Johns Hopkins Medicine]

5.9.5 AACR - CAR-T

New Adoptive Cell Therapy Immunotherapy Approach Ready for Clinical Trials [Roswell Park Cancer Institute]

Kite Presents Promising Preclinical Data from KITE-585, a Fully Human Anti-BCMA CAR T-Cell Product Candidate at the 2017 American Association of Cancer Research (AACR) Annual Meeting [Kite]

5.9.7 AACR - divers

IDH-mutant Cancers May be More Amenable to PARP Inhibitors Than IDH Inhibitors [AACR]

5.9.9 AACR - immunothérapies

Bristol-Myers joins the IDO rush with its own in-house combo program for Opdivo [EndPoints]

NewLink grabs the AACR spotlight with IDO pathway, Keytruda combo — shares blitzed [EndPoints]

Bristol-Myers’ checkpoint star Opdivo fails a PhIII study for glioblastoma [EndPoints]

6. Lutte contre les cancers

Jeffrey Aronson: When I use a word . . . Translational research—an early model [BMJ Blogs]

6.10 Politiques

Brexit: As Article 50 is triggered, what’s next for UK science and patients? [Cancer Research UK]

6.10.1 Politiques (USA)

What Trump gets wrong about drug companies [STAT]

6.5 Médecines alternatives

Belle Gibson mimicked countless fake healers. They aren't delusional [The Guardian]

6.6 Publications

Announcing Unpaywall: unlocking #openaccess versions of paywalled research articles as you browse [LSE]

For problematic papers, don’t retract or correct, say publishing experts: Amend [Retraction Watch]

“Failure is an essential part of science:” A Q&A with the author of a new book on reproducibility [Retraction Watch]

Unpaywall finds free versions of paywalled papers [Nature]